The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01702194
: October 5, 2012
Last Update Posted
: September 5, 2014
Theravance Biopharma R & D, Inc.
Information provided by (Responsible Party):
Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. )
The purpose of this study is to determine TD-1211 is processed by the body.
Condition or disease
Drug: TD-1211 IV [C14]Drug: TD-1211 PO [C14]
This study will provide information regarding the metabolic pathway of TD 1211, the need for evaluation of potential drug-drug interactions, the need for studies in special populations and the absolute oral bioavailability of TD-1211. The administration of radiolabeled drug is necessary to fully characterize the rates and routes of elimination of TD 1211, providing further quantitative information on the disposition of TD 1211. The results from this study will allow a more comprehensive comparison between animal and human routes of elimination and metabolic profiles of TD 1211.
A Single-Dose, Fixed-Sequence, Two-Period, Two−Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD−1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD−1211 in Healthy Male Subjects
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy, nonsmoking male, 18 to 50 years old, inclusive.
Agrees to use a highly effective method of birth control.
Body mass index (BMI) 19 to 30 kg/m2, inclusive, and weighs at least 55 kg.
Willing and able to give written informed consent.
Evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.
Hemoglobin <14.1 g/dL or hematocrit < 40.6% at Screening.
History of hypersensitivity to drugs, or a history of or any current clinically significant hypersensitivities.
Any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]).
Participated in another clinical trial of an investigational drug (or medical device) within 60 days (or 5 half-lives of the investigational drug, whichever is longer) prior to Screening, or is currently participating in another trial of an investigational drug (or medical device).